Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol

References

• Arnett DK, Blumenthal RS, Albert MA, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74:e177–e232.
   PubMed Web of Science ®Google Scholar
• Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med. 1964;61:888–899.
   PubMed Web of Science ®Google Scholar
• Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2015;36:774–776.
   PubMed Web of Science ®Google Scholar
• Brunner FJ, Waldeyer C, Ojeda F et al. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. (Lancet). 2019.
   Google Scholar
• Baigent C, Blackwell L, Emberson, J., Holland, L. E., Reith, C., Bhala, N., … & Collins, R., Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Martin SS, Blumenthal RS, Miller M. LDL cholesterol: the lower the better. Med Clin North Am. 2012;96:13–26.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative G. MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
   PubMed Web of Science ®Google Scholar
• Xiao C, Dash S, Morgantini C, et al. Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond Lowering LDL cholesterol. Diabetes. 2016;65:1767–1778.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1–10.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18:C2–C12.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23:799–807.
   PubMed Web of Science ®Google Scholar
• Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–2989.
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–730.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14:401–411.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5:319–335.
   PubMed Web of Science ®Google Scholar
• Ference BA, Kastelein JJP, Ray KK, et al. Association of Triglyceride-Lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364–373.
   PubMed Web of Science ®Google Scholar
• Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: a collaborative approach. Circulation. 2005;112:3184–3209.
   PubMed Web of Science ®Google Scholar
• Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–366.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. (U.S Food and Drug Administration Website). 2019.
   Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
   PubMed Web of Science ®Google Scholar
• Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Grunfeld C. Triglyceride lowering drugs. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.,; 2018. p. 1–52.
   Google Scholar
• Zimetbaum P, Frishman WH, Kahn S. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol. 1991;31:25–37.
   PubMed Web of Science ®Google Scholar
• Group AS. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–1861.
   PubMed Web of Science ®Google Scholar
• Elam M, Lovato LC, Ginsberg H. Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Curr Opin Lipidol. 2011;22:55–61.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.
   PubMed Web of Science ®Google Scholar
• Zhao S, Wang F, Dai Y, et al. Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. Int J Cardiol. 2016;221:832–836.
   PubMed Web of Science ®Google Scholar
• Remick J, Weintraub H, Setton R, et al. Fibrate therapy: an update. Cardiol Rev. 2008;16:129–141.
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol. 2013;24:239–245.
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–197.
   PubMed Web of Science ®Google Scholar
• Group HTC. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291.
   PubMed Web of Science ®Google Scholar
• Investigators A-H, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267.
   PubMed Web of Science ®Google Scholar
• Tatachar A, Pio M, Yeung D, et al. Over-the-counter fish oil use in a county hospital: medication use evaluation and efficacy analysis. J Clin Lipidol. 2015;9:326–333.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Manku MS, Bays HE, et al. Icosapent Ethyl effects on fatty acid profiles in statin-treated patients with high triglycerides: the randomized, Placebo-controlled ANCHOR study. Cardiol Ther. 2019;8:79–90.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. (Update on Phase III STRENGTH trial for Epanova in Mixed Dyslipidimia). 2020.
   Google Scholar
• Nicholls SJ, Lincoff AM, Bash D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281–1288.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendia LE, Mikhailidis DP, et al. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2018;50:565–575.
   PubMed Web of Science ®Google Scholar
• Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 polyunsaturated fatty acid (Fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135:e867–e884.
   PubMed Web of Science ®Google Scholar
• Bays HE, Ballantyne CM, Kastelein JJ, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108:682–690.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–992.
   PubMed Web of Science ®Google Scholar
• Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673–e691.
   PubMed Web of Science ®Google Scholar
• Nomura S, Shouzu A, Omoto S, et al. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J Atheroscler Thromb. 2009;16:83–90.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Irino Y, Shinohara M, et al. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit anti-atherogenic properties. Circ J. 2018;82:596–601.
   PubMed Web of Science ®Google Scholar
• Orringer CE, Jacobson TA, Maki KC. National lipid association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13:860–872.
   PubMed Web of Science ®Google Scholar
• VASCEPA. (VASCEPA Label). 2019.
   Google Scholar
• Weintraub HS. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia. Postgrad Med. 2014;126:7–18.
   PubMed Web of Science ®Google Scholar
• Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197:12–24.
   PubMed Web of Science ®Google Scholar
• Chambrier C, Bastard JP, Rieusset J, et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes Res. 2002;10:518–525.
   PubMedGoogle Scholar
• Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res. 2003;44:455–463.
   PubMed Web of Science ®Google Scholar
• Nelson JR, Raskin S. The eicosapentaenoic acid: arachidonicacid ratio and its clinical utility in cardiovascular disease. Postgrad Med. 2019;131:268–277.
   PubMed Web of Science ®Google Scholar
• Kashiyama T, Ueda Y, Nemoto T, et al. Relationship between coronary plaque vulnerability and serum n-3/n-6 polyunsaturated fatty acid ratio. Circ J. 2011;75:2432–2438.
   PubMed Web of Science ®Google Scholar
• Nagahara Y, Motoyama S, Sarai M, et al. Eicosapentaenoic acid to arachidonic acid (EPA/AA) ratio as an associated factor of high risk plaque on coronary computed tomography in patients without coronary artery disease. Atherosclerosis. 2016;250:30–37.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Effects of Icosapent Ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73:2791–2802.
   PubMed Web of Science ®Google Scholar
• Association FaD. (FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups). 2019, Dec 13.
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 10. cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103–S123.
   PubMed Web of Science ®Google Scholar
• Mason RP. New insights into mechanisms of action for Omega-3 fatty acids in atherothrombotic cardiovascular disease. Curr Atheroscler Rep. 2019;21:2.
   PubMed Web of Science ®Google Scholar
• Perez-Martinez P, Katsiki N, Mikhailidis DP. The role of n-3 fatty acids in cardiovascular disease: back to the future. Angiology. 2020;71:10–16.
   PubMed Web of Science ®Google Scholar
• Harris WS. Understanding why REDUCE-IT was positive - Mechanistic overview of eicosapentaenoic acid. Prog Cardiovasc Dis. 2019;62:401–405.
   PubMed Web of Science ®Google Scholar
• Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2019. DOI:10.1007/s11883-019-0762-1
   PubMed Web of Science ®Google Scholar
• Lakshmanan S, Shekar C, Kinninger A, et al. Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography. Cardiovasc Res. 2020;116:479–482.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Mason RP. Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction. Chem Phys Lipids. 2018;212:73–79.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Mason RP. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496:335–338.
   PubMed Web of Science ®Google Scholar
• Budoff MJ, Roy S, Tayek J, et al. Effect of Icosapent Ethyl on progression of coronary Atherosclerosis in patients with elevated Triglycerides on Statin therapy - EVAPORATE. Philadelphia, PA: Annual Scientific Sessions of the American Heart Association; 2019. p.16–18. https://www.abstractsonline.com/pp8/#!/7891/presentation/35090
   Google Scholar
• Watanabe T, Ando K, Daidoji H, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537–544.
   PubMed Web of Science ®Google Scholar